KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Accumulated Expenses (2016 - 2025)

TherapeuticsMD's Other Accumulated Expenses history spans 16 years, with the latest figure at $301000.0 for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $301000.0; the TTM value through Sep 2025 reached $301000.0, changed N/A, while the annual FY2024 figure was $88000.0, 78.48% down from the prior year.
  • Other Accumulated Expenses reached $301000.0 in Q3 2025 per TXMD's latest filing, up from $202000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $59.2 million in Q2 2022 to a low of $88000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 5 years is $16.2 million, with a median of $11.5 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: soared 580.86% in 2021, then crashed 97.83% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $13.3 million in 2021, then soared by 41.3% to $18.8 million in 2022, then plummeted by 97.83% to $409000.0 in 2023, then plummeted by 78.48% to $88000.0 in 2024, then soared by 242.05% to $301000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Other Accumulated Expenses are $301000.0 (Q3 2025), $202000.0 (Q2 2025), and $249000.0 (Q1 2025).